{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-042756","form_type":"8-K","ticker":"VRCA","cik":"0001660334","company_name":"Verrica Pharmaceuticals Inc.","filed_at":"2023-02-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.045177+00:00","generated_at":"2026-06-19T07:03:52.647047+00:00","sec_items":["2.02","8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Verrica reports $34.3M cash; updates on VP-102 NDA and VP-315 Phase 2 trial","bullets":["Preliminary cash and cash equivalents of $34.3M as of Dec 31, 2022, unaudited and subject to change.","NDA for VP-102 (molluscum contagiosum) resubmitted Jan 23, 2023; PDUFA goal date expected H2 2023.","New CMO partner Piramal Pharma Solutions selected; technology transfer completed Jan 2023.","VP-315 Phase 2 Part 1 (10 patients) showed favorable safety, no serious adverse events; Part 2 to start Q2 2023.","Phase 3 trial for VP-102 (external genital warts) expected to initiate H2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-042756","json":"https://secwatch.observer/filing/0001193125-23-042756.json","markdown":"https://secwatch.observer/filing/0001193125-23-042756.md","text":"https://secwatch.observer/filing/0001193125-23-042756.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1660334/000119312523042756/0001193125-23-042756-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1660334/000119312523042756/d467166d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T07:03:52.647047+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d638f689c1a6f3b5538713cbbc5eb1c42bf94e56","claim":"Verrica Pharmaceuticals Inc. reported preliminary financial results for the year ended December 31, 2022.","evidence_excerpt":"On February 21, 2023, Verrica Pharmaceuticals Inc. (the “ Company ”) reported that, as of December 31, 2022, it had approximately $34.3 million of cash and cash equivalents.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1660334/000119312523042756/0001193125-23-042756-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}